|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 405/04 | (2006.01) |
| C07C 309/19 | (2006.01) | ||
| C07C 309/29 | (2006.01) | ||
| C07C 309/35 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 31/47 | (2006.01) |
| (11) | Number of the document | 3823617 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19842049.9 |
| Date of filing the European patent application | 2019-07-22 | |
| (97) | Date of publication of the European application | 2021-05-26 |
| (45) | Date of publication and mention of the grant of the patent | 2024-03-06 |
| (46) | Date of publication of the claims translation | 2024-07-10 |
| (86) | Number | PCT/US2019/042827 |
| Date | 2019-07-22 |
| (87) | Number | WO 2020/023391 |
| Date | 2020-01-30 |
| (30) | Number | Date | Country code |
| 201862701726 P | 2018-07-21 | US |
| (72) |
NATALE, Christopher , US
MOONEY, Patrick , US
GARYANTES, Tina , US
LUKE, Wayne , US
|
| (73) |
Linnaeus Therapeutics, Inc. ,
30 Washington Ave Suite F, Haddonfield NJ 08033,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Enantiomeriškai išgrynintas GPER agonistas, skirtas naudoti gydant ligas ir būkles |
| ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS |
| Payment date | Validity (years) | Amount | |
| 2025-06-19 | 7 | 162.00 EUR |
| 2026-07-22 |